A
Alltrna
Pioneering the use of tRNA to treat disease
About Alltrna
Alltrna is a pioneering biotech startup that operates in the field of tRNA therapeutics. The company is the first of its kind to decode tRNA biology and utilize it to develop treatments for a wide range of diseases. Transfer RNA (tRNA) is a molecule that plays a crucial role in protein synthesis, which is fundamental to life and disease treatment. Despite its importance, the potential of tRNA has been largely unexplored until now.
Read full description
Alltrna's business model revolves around controlling tRNA to regulate protein synthesis and address diseases at their source. One of their key applications involves treating diseases caused by a specific genetic mutation known as a "nonsense mutation". This mutation changes the code for an amino acid into a "stop" codon, resulting in a shortened protein that causes disease. Alltrna has developed tRNAs that can read these stop codons and deliver the correct amino acid, restoring the production of the full-length protein. This approach has the potential to treat thousands of diseases that share the same genetic mutation.
The company's clients are primarily patients suffering from diseases caused by this genetic mutation. Alltrna's revenue is generated through the development and sale of their tRNA therapeutics. The company's team consists of experts in various fields, including a Chief Executive Officer, Chief Scientific Officer, Chief Innovation Officer, Chief Financial Officer, Chief Technology Officer, and several Vice Presidents overseeing different departments.
At a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Cambridge, United States
- Employees
- 50
- Open positions
- 1
- Dealroom signal
- 29.6/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Core AI, RNA, Techbio, Hard Tech, AI Applications, proteomics, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Alltrna.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Aug 2023 | $109M | $436M | Flagship Pioneering | ↗ |
| EARLY VCOther financing | Nov 2021 | $50M | $200M | Flagship Pioneering | ↗ |
Growth signals
Latest recorded traffic for Alltrna is 6.2K monthly website visits, down 30.3% over the last three months. Alltrna's team declined 26.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alltrna on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alltrna’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.